Introduction: Th e prevalence of Non-alcoholic fatty liver disease (NAFLD) has increased in the last two decades & there has been growing evidence in regard to the association between NAFLD/Nonalcoholic steatohepatitis and both thyroid dysfunction and obstructive sleep apnea. Methods: A retrospective analysis was performed using the National Inpatient Sample(NIS) database for 2010. Th e NIS is the largest inpatient health care database in US. Th e variables included in this study were identifi ed using ICD9 codes for 2010. ICD9 Codes (5718), (2449) and (327.23) that represent NAFLD, hypothyroidism and OSA respectively. An equal number of non-NAFLD patients were randomly selected out of the 7 million admissions. A Case-Control design was used to compare the cohorts. A binary and multiple logistic regression statistical test was used. IBM SPSS Statistics for Windows was used to execute the analysis. A confi dence interval (CI) of 95% and P value less than 0.05 were determined to defi ne signifi cance. Results: Approximately 32,000 patients with NASH and randomly selected 28,000 without NASH were identifi ed for the study. Within the NASH group, 4,097 (11%) were found to have coexisting hypothyroidism, and 4,213 (12.7%) patients of the Non-NASH group had hypothyroidism. Patients with hypothyroid disease has almost the same probability of having NASH compared to individuals without hypothyroidism (Crude odds ratio is 1.1, Adjusted odd ratio is 0.7, CI 95%, P0.00). In the NASH group, 937 (2.5%) were found to have OSA, whereas (1.25%) 383 patients only have OSA in the Non-NASH group. (See table3). People with obstructive sleep apnea have 2.3 higher probabilities to have NASH than people without history of sleep apnea. (Crude odd ratio is 2.3. Adjusted odd ratio is 1.72, P 0.00, CI 95%). As far as other associated commorbities, 31% of NASH patient group had diabetes and 69% did not. 53.9% had HTN and 46.1% did not. 27.1% of the NASH population was obese while 72.9% was not. Obese patients were 4 times more likely to have NASH than non-obese people. (Crude odd ratio 4.1, adjusted odd ration 3.6, CI (3.9-4.3), P value of 0.00). Diabetic individuals were about 3 times more likely to have NASH than non diabetic. (Crude Odd ratio of 2.7, adjusted odd ratio 2.3, CI 2.6-2.8, P value of 0.00.). Conclusion: People with obstructive sleep apnea are almost two times more likely to have NAFLD than people without obstructive sleep apnea. On the other hand, Hypothyroidism was not found to be a risk for NAFL
Introduction: Hepatocellular carcinoma (HCC) is the 6th incidence of cancer in world and 3rd cause of cancer mortality. To fi nd out diff erential expression of apolipoproteins-ApoAI and ApoAIV in HCC and controls without HCC and comparison of ApoAI and ApoAIV expression with AFP conventional marker in HCC. Methods: 50 HCC cases and a total of 50 controls comprise liver cirrhosis (n=25) and chronic hepatitis (n=25) without HCC was included in this study. Total proteins were precipitated using acetone precipitation method followed by Albumin and IgG depletion of precipitated protein using depletion kit. Proteins were then separated by SDS PAGE. Th e expression changes of ApoAI and ApoAIV were confi rmed by Western Blotting using specifi c primary and secondary polyclonal antibody followed by densitometric protein semiquantitative estimation. Apo-AI, ApoAIV and AFP were measured in blood plasma samples by ELISA method according to the manufacturer's protocol. Results: Semi-quantitativedensitometry image analysis of the western blots images and the comparison between patients with and without HCC revealed diff erential expression of ApoAI and ApoAIV. Levels of ApoAI were signifi cantly higher in patients with HCC compared to controls without HCC (0.279 ± 0.216 versus 0.171 ± 0.091 & 0.199±.014; P = 0.0001). Levels of Apo-AIV were signifi cantly lower in patients of HCC compared to controls without HCC (0.119 ± 0.061 versus 0.208 ± 0.07 & 0.171± 0.16; P =0.008). Apo-AI and ApoAIV was further measured and compared to AFP estimation by ELISA. Elisa assays of Apo lipoproteins -ApoAI and ApoAIV revealed the supportive results of expression of ApoAI and ApoAIV in western blotting densitometry image analysis in current study. Conclusion: Apolipoprotein AI is highly expressed in HCC compared to controls without HCC and may be used as future diagnostic tool in addition and associated with other conventional biomarkers for screening of HCC cases.
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Hepatic Granulomas: Looking for a Battlefi eld on More Th an 9000 Biopsies Rui Gaspar, MD 1 , Patrícia Andrade, MD 1 , Marco Silva, MD 1 , Armando Peixoto, MD 1 , Rosa Coelho, MD 1 , Joanne Lopes, PhD 1 , Fátima Carneiro, PhD 1 , Guilherme Macedo, MD, PhD, FACG, FASGE, FAASLD, AGAF 2 . 1. Centro Hospitalar de São João, Porto, Porto, Portugal; 2. Centro Hospitalar de São João, Oporto, Porto, Portugal. Introduction: Hepatic granulomas have an estimated incidence of 5% in liver biopsies, with a wide range of etiologies all over the world. Our aim was to assess the relative importance, as well as their presenting features and underlying etiology, in a tertiary university hospital, from a western country Methods: We underwent a retrospective study of all the liver biopsies (9374) performed in our centre from the period extending from January 1998 to December 2015. We have reviewed all the medical reports, laboratory data and imaging exams in order to determine the liver granuloma etiologies Results: During the 18 years of our study, a total of 297 hepatic granulomas were found in 9374 biopsies. Th e most common etiology was tuberculosis (29.3%), followed by NASH and PBC. In 33 patients (11.1%) the available investigations did not lead to an etiological diagnosis and were classifi ed as idiopathic. Till 2004, we found 142 granulomas and aft er 2004 we found 155 granulomas. We observed a shift in granulomas' etiology, being the infectious agents responsible for the vast majority of cases before 2004 (56.3%), with tuberculosis the primary cause. However, aft er 2004, the infectious causes accounted only 25.5% of the granulomas, while NASH (24%) and auto-immune diseases (35.6%) became the most common causes. We found out 6 cases of drug reaction granulomas in the last period of time (aft er 2004) caused by alopurinol, etanercept, chemiotherapy, fi brate and two by anti-retrovirals (3.9%). Concerning granulomas caused by infectious agentes, tuberculosis was responsible for 87 cases and there were sporadic cases of schistosomiasis, Q fever, leishmaniosis, hepatic candidiasis, cryptococcosis and CMV infection. Conclusion: We found an incidence of hepatic granulomas of 3.2% in the 9374 biopsies performed during the 18 years of our study. Th e most common etiologies were tuberculosis, NASH and PBC. As reported in Western countries, we found and epidemiological shift towards the non infectious causes, with NASH and auto-immune diseases being the most common etiologies of hepatic granulomas nowadays. Drug induced granulomatous hepatitis may be increasing its relevance (3.8% aft er 2004). 
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AST Levels and APRI Index in Patients with ESRD and HCV
